HC Wainwright reiterates Buy on Celldex Therapeutics with $64 price target

HC Wainwright & Co. reiterated their Buy rating on Celldex Therapeutics's stock with a price target of $64.00. The price target implies an upside of 98.9% from the Oct 1 close of $32.18.